Journal article icon

Journal article

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

Abstract:

Background

The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight)... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/NEJMoa2100433

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Role:
Author
ORCID:
0000-0003-4309-9162
et al.

Contributors

Role:
Contributor
Publisher:
Massachusetts Medical Society
Journal:
New England Journal of Medicine More from this journal
Volume:
384
Issue:
16
Pages:
1491-1502
Publication date:
2021-02-25
Acceptance date:
2021-02-09
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Language:
English
Keywords:
Pubs id:
1161185
Local pid:
pubs:1161185
Deposit date:
2021-02-12

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP